Chemours Sees Sales at High End of Range, But Adjusted Ebitda Falls Below Estimates-- Update

Dow Jones
Jun 18, 2025
 

By Denny Jacob

 

Chemours forecasts second-quarter sales to be high end of its prior range, helped by increased sequential growth in a key segment.

The chemicals company previously forecast overall sales to increase in the low to mid-teens sequentially from first-quarter revenue of $1.37 billion and consolidated adjusted earnings before interest, taxes, depreciation and amortization to be up between 40% and 45%.

Chemours on Wednesday also disclosed second-quarter adjusted Ebitda is now projected to range between $215 million and $225 million. Analysts polled by FactSet expected $236 million.

By segment, thermal & specialized solutions is expected to see a sequential increase in sales of about 25% on demand for Opteon refrigerants. Adjusted Ebitda is expected to be up sequentially by nearly 40%.

Advanced performance materials, meanwhile, is anticipated to be within original expectations of low teens sequential growth but adjusted Ebitda is expected to rise 25% sequentially.

Titanium technologies is expected to report sales in line with the segment's high single-digit growth expectations. Adjusted Ebitda, however, is seen down 15% sequentially because of operational disruptions, mainly caused from a rail line service interruption that affected feedstock mix. The issue led to higher costs totaling $15 million while costs from other disruptions is expected at about $10 million, the company said.

Chemours also expects overall corporate costs to be slightly higher in the second quarter due to a continuing pollution trial in New Jersey.

The company is accused of violating environmental laws linked to manufacturing operations at a southern New Jersey site.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

June 18, 2025 09:03 ET (13:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10